Further clinical analysis using tumor samples and functional study using in vivo cancer models may provide a comprehensive view of the role of SET7/9 in cancer initiation and progression, which can help better evaluate the clinical value of SET7/9 as a potential risk predictor or therapy target. The gene discussed is SETD7; the disease is neoplasm.